Rapivab (peramivir) is an injectable anti-viral drug approved for the treatment of acute uncomplicated influenza in patients 2 years of age and older who have been symptomatic for no more than 2 days. This product is approved to treat Type A and B influenza; however, the majority of patients included in the studies were infected with type A, the most common in the U.S. The efficacy of Rapivab could not be established in patients with serious influenza requiring hospitalization.
Rapivab is not approved for the prevention of influenza.
Rapivab is not a substitute for early influenza vaccination on an annual basis.